• Christopher Hayward, Iki Adachi, Sylvie Baudart, Erin Davis, Erika D Feller, Koichiro Kinugawa, Liviu Klein, Song Li, Angela Lorts, Claudius Mahr, Jacob Mathew, Michiel Morshuis, Marcus Müller, Minoru Ono, Francis D Pagani, Federico Pappalardo, Jonathan Rich, Desiree Robson, David N Rosenthal, Diyar Saeed, Christopher Salerno, Andrew J Sauer, Thomas Schlöglhofer, Laurens Tops, and Christina VanderPluym.
• Heart Failure and Transplant Unit, St Vincent's Hospital, Sydney, Australia. Electronic address: cshayward@stvincents.com.au.
• J. Thorac. Cardiovasc. Surg. 2022 Oct 1; 164 (4): 1120-1137.e2.

ObjectivesSix months after withdrawal of the HeartWare HVAD System (HVAD; Medtronic) from sale, approximately 4000 patients continue ongoing support with this device. In light of the diminishing experience, this global consensus document summarizes key management recommendations.MethodsInternational experts with experience in the management of patients with ongoing HVAD support were invited to summarize key aspects of patient and pump management and highlight differences in the current HeartMate 3 (Abbott Laboratories) ventricular assist device. Clinicians from high-implanting HVAD sites reviewed current literature and reported experience to generate a consensus statement.ResultsSpecific guidelines to assist in the management of ongoing HVAD patients are developed. Key management protocols and helpful techniques developed from experienced clinicians are combined into a short guideline document. As experience with HeartMate 3 increases, key differences in approach to management are highlighted, where appropriate.ConclusionsWith decreasing worldwide experience in the ongoing management of HVAD-supported patients, this consensus guideline provides a summary of best practice techniques from international centers. Differences in HeartMate 3 management are highlighted.Copyright © 2022 The Authors. Published by Elsevier Inc. All rights reserved.

12 keywords...

hide…